Quoin Pharmaceuticals Receives FDA IND Clearance to Initiate Phase 2 Study of QRX003 in Peeling Skin Syndrome
Go back to Quoin Pharmaceuticals Receives FDA IND Clearance to Initiate Phase 2 Study of QRX003 in Peeling Skin Syndrome| (NASDAQ: QNRX) | Delayed: 4.79 +0.22 (4.81%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $4.57 | 52 Week High | $ | |||
| Open | $4.79 | 52 Week Low | $ | |||
| Day High | $4.90 | P/E | N/A | |||
| Day Low | $4.70 | EPS | $ | |||
| Volume | 17,367 | |||||
